ulcerative colitis and semaglutide Semaglutide and Colitis: Safety Considerations for IBD Patients Semaglutide-Induced Small Bowel Pseudo-Obstruction and

TrimRX Weight Loss Programs The high costs of GLP-1 therapies underscore the need for practical, accessible solutions

FDA indications According to the Prescribing Information, the wording of the FDA indications for semaglutide injection (Wegovy ) is as follows (the emphasis below in red has been added by us): WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight

Sources 1

La doctora Monereo cuenta con varios premios cientficos concedidos por la Academia Mdico Quirrgica, la Sociedad Espaola de Endocrinologa y Nutricin y la Sociedad Espaola para el estudio de la Obesidad en distintas ediciones